Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 8/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396378 | 0.90 | MLNR (0.45) | MLNRFAAHCHRM4CYP3A4PGR | |
| SCHEMBL377798 | 0.88 | KDM4E (0.49) | MLNRFAAHCYP3A4DRD4 | |
| SCHEMBL377935 | 0.86 | FAAH (0.42) | MLNRFAAHCYP3A4DRD4MGLL | |
| SCHEMBL1313152 | 0.86 | MLNR (0.56) | MLNRFAAHCHRM4CYP3A4 | |
| SCHEMBL377805 | 0.85 | MLNR (0.56) | MLNRCYP3A4CYP2D6 | |
| SCHEMBL377511 | 0.84 | MLNR (0.58) | MLNRFAAHCYP3A4CYP2D6 | |
| SCHEMBL377495 | 0.82 | MLNR (0.54) | MLNRCYP3A4CYP2D6 | |
| SCHEMBL2396382 | 0.81 | MLNR (0.43) | MLNRFAAHCYP3A4DRD4ACHE | |
| SCHEMBL4210797 | 0.80 | MLNR (0.55) | MLNRCYP3A4CYP2D6 | |
| SCHEMBL378267 | 0.80 | MLNR (0.55) | MLNRCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236953-B2 | Process for preparing piper azine derivatives | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-2029538-B1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | SEAL JONATHAN THOMAS | 2011-11-10 | — | — | US | disclosed |
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | MLNR 6/4885FAAH 1304/4885CHRM4 395/4885 |
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | MLNR 6/4885FAAH 1304/4885CHRM4 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.